EUVIMEDEUVIMED entdecken
Open Access

Alcohol dehydrogenase 4 and aldo-keto reductase 1A1 catalyze the oxidation of 4-hydroxytolbutamide, a metabolite of tolbutamide, in the human liver

Kazuya Shimomura, Rei Sato, Miyu Watanabe, Yuichiro Higuchi, Shotaro Uehara, Nao Yoneda, Masataka Nakano, Hiroshi Suemizu, Miki Nakajima, Tatsuki Fukami

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Kazuya Shimomura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: Liver, Alcohol Dehydrogenase, Tolbutamide, Aldehyde Reductase. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Worcester Polytechnic Institute, Mochida Memorial Foundation for Medical and Pharmaceutical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tolbutamide is metabolized by cytochrome P450 2C9 into 4-hydroxytolbutamide (4-OH TB), which retains pharmacological activity. 4-OH TB is further oxidized to the inactive metabolite 4-carboxytolbutamide, likely via the intermediate tolbutamide aldehyde (4-CHO TB). Because the conversion of 4-OH TB to 4-CHO TB is considered the rate-limiting step, the enzyme(s) catalyzing this reaction may play a crucial role in determining drug efficacy. We aimed to identify the enzyme(s) responsible for this process in the human liver. 4-CHO TB was formed from 4-OH TB in human liver cytosol (HLC) in the presence of nicotinamide-adenine dinucleotide (NAD+). The relative activity factor approach revealed that this reaction was primarily attributed to alcohol dehydrogenase 4 (ADH4). Interestingly, 4-CHO TB was also formed in HLC in the presence of nicotinamide-adenine dinucleotide phosphate (NADP+), with a 1.6-fold higher intrinsic clearance than that of NAD+. Untargeted proteomic analysis revealed a significant correlation between aldo-keto reductase 1A1 (AKR1A1) protein levels and NADP+-dependent 4-CHO TB formation in 15 HLC samples (r = 0.627, P < .05). Recombinant AKR1A1 effectively catalyzed this reaction, contributing 92% of NADP+-dependent 4-CHO TB formation in HLC. Based on hepatic NAD+ and NADP+ concentrations and the expression levels of ADH4 and AKR1A1, AKR1A1 was estimated to contribute one-third of ADH4 to 4-CHO TB formation in the human liver. In conclusion, we demonstrated that ADH4 and AKR1A1 jointly mediate the oxidation of 4-OH TB to 4-CHO TB in the human liver, highlighting the novel role of AKR1A1 as an oxidase in drug metabolism. SIGNIFICANCE STATEMENT: This study identifies aldo-keto reductase 1A1 as a novel enzyme involved in the oxidation of 4-hydroxytolbutamide in the human liver. Alongside alcohol dehydrogenase 4, aldo-keto reductase 1A1 contributes to NADP+-dependent aldehyde formation, suggesting a previously unrecognized role in drug metabolism and variability in tolbutamide clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverAlcohol DehydrogenaseTolbutamideAldehyde ReductaseHumansOxidation-ReductionNADPCytosolMaleNADAdult

Stichwörter der Autor:innen

4-HydroxytolbutamideADH4AKR1A1Aliphatic alcohol oxidation

Substanzen

Alcohol DehydrogenaseTolbutamidealcohol dehydrogenase IVAKR1A1 protein, humanNADPNADAldehyde Reductase

Autor:innen und Institutionen

  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
  • Liver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Medicine and Life Science (CIEM), Kawasaki, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Japan. Electronic address: tatsuki@…

Förderung

  • Worcester Polytechnic Institute
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research

Zitieren

APA

Shimomura, K., Sato, R., Watanabe, M., Higuchi, Y., Uehara, S., Yoneda, N., Nakano, M., Suemizu, H., Nakajima, M., & Fukami, T. (2025). Alcohol dehydrogenase 4 and aldo-keto reductase 1A1 catalyze the oxidation of 4-hydroxytolbutamide, a metabolite of tolbutamide, in the human liver. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100173

Vancouver

Shimomura K, Sato R, Watanabe M, Higuchi Y, Uehara S, Yoneda N, et al. Alcohol dehydrogenase 4 and aldo-keto reductase 1A1 catalyze the oxidation of 4-hydroxytolbutamide, a metabolite of tolbutamide, in the human liver. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100173

BibTeX
@article{Shimomura2025,
  author = {Shimomura, Kazuya and Sato, Rei and Watanabe, Miyu and Higuchi, Yuichiro and Uehara, Shotaro and Yoneda, Nao and Nakano, Masataka and Suemizu, Hiroshi and Nakajima, Miki and Fukami, Tatsuki},
  title = {Alcohol dehydrogenase 4 and aldo-keto reductase 1A1 catalyze the oxidation of 4-hydroxytolbutamide, a metabolite of tolbutamide, in the human liver},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100173}
}
Kostenlos starten →